NKGN Stock Alert: The Alzheimer's News That Has NKGen Biotech Soaring Today

NKGen Biotech (NASDAQ:NKGN) stock is taking off on Monday after the clinical-stage biotechnology company got an update on its Phase 2 clinical trial. The company says that its Safety Review Committee has given it the go-ahead to start its Phase 2 clinical study of SNK01. This is a drug in development by the company to treat moderate Alzheimer's. This comes after it reported stellar results from its Phase 1 clinical trial. That includes improved or maintained cognitive abilities after four doses. There were ...